Rare Immunology News
Advertisement
Spotlight On
Alopecia totalis (AT)
Alopecia totalis is the loss of all skull and facial hair
Prevalence
30 / 100,000
Age of Onset
ICD-10
#N/A
Inheritance
This condition does not appear to have a clear pattern of inheritance.
Rare View
Alopecia areata (AA) is a chronic, autoimmune disorder of non-scarring hair loss mediated by T-lymphocytes against the hair follicular unit. Alopecia totalis (AT) is a condition characterized by the complete loss of hair on the scalp. It is an advanced form of alopecia areata a condition that causes round patches of hair loss.
5 Facts you should know
FACT
A condition characterized by the complete loss of hair on the scalp
FACT
An advanced form of alopecia areata
FACT
It is thought to be an autoimmune condition in which the immune system mistakenly attacks the hair follicles
FACT
Roughly 20% of affected people have a family member with alopecia
FACT
Among those in whom all body hair is lost, fewer than 10% recover
Interest over time
Google searches
Common signs & symptoms
Alopecia of scalp
Current treatments
There is no cure, and available treatments are not usually effective for severe alopecia totalis.
Top Clinical Trials
Title | Description | Phases | Status | Interventions | More Information |
---|---|---|---|---|---|
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA | This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA). | Phase 2 | Active, not recruiting | Drug: PF-06651600|Drug: Placebo | More Info |
Long-Term PF-06651600 for the Treatment of Alopecia Areata | This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. | Phase 3 | Active, not recruiting | Drug: PF-06651600|Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine|Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine | More Info |